From any solid tumor, for any patient, administered safely in any clinical setting.
“This is a treatment that is easy to use and my patients love the idea of using their own cells to treat their cancer.”
Elios Site InvestigatorTLPLDC: Tumor Lysate, Particle-loaded, Dendritic Cell
Two decades of clinical development of the Elios therapeutic cancer vaccine
Elios Therapeutics, LLC, is a biopharmaceutical company developing a portfolio of innovative therapeutic cancer vaccines targeting unmet medical needs across a broad range of tumor types. Elios’ lead product, TLPLDC, is a personalized therapeutic cancer vaccine designed to attack cancer cells by igniting innate and adaptive immune responses which increase a patient’s own production of T cells to fight their specific cancer.
There remains a need for effective adjuvant treatments for high risk, resectable melanoma
A significant proportion of late-stage melanoma patients will ultimately experience a poor prognoses
Elios by the numbers:
ELIOS is developing a portfolio of innovative therapeutic cancer vaccines targeting unmet medical needs across a broad range of tumor types:
With our novel approach to the development of safe and efficacious therapeutic cancer vaccines, Elios is poised to realize the power of personalized medicine and transform how we treat cancer.
Contact us to learn more about our company and how we are advancing the promise of personalized therapeutic cancer vaccines to improve the lives of people with cancer around the world.
Contact us